Bayer halves the price of its contraceptive implant Jadelle® for women in developing countries
Bayer will halve the price of its contraceptive implant Jadelle until 2023 for women living in poor countries around the world. According to the Reproductive Health Supply Coalition the demand for implants is increasing continuously in these countries. Bayer's "Jadelle Access Program" aims to make this underutilized method more affordable and accessible to women there, ultimately helping them to expand their choice of contraceptive options.
"Our 'Jadelle Access Program' widens the contraceptive options available to women living in poor countries around the world, so they can choose a method that best suits their needs," said Dieter Weinand, member of the Board of Management of Bayer AG and President of its Pharmaceuticals Division.
'Ensure healthy lifes and promote well-being for all at all ages', is one of the Sustainable Development Goals (SDGs) ratified in September 2015 by the United Nations. These goals set a large number of ambitious targets to be achieved by 2030. They all recognize "health" as a driver of global economic growth. Although only specifically covered by one goal, health is implicitly linked to most of the other 16 SDGs.
Bayer’s activities in family planning directly relate to the "Health" goal, as it covers among others child and maternal mortality and reproductive health. As a market leader in oral contraceptives, Bayer now has nearly 50 years of expertise in the field of family planning. For women in developing countries, Bayer supplies its different hormonal contraceptive methods to partners in international development cooperation at a preferential price. At the same time, Bayer is developing new concepts like the "Jadelle Access Program" to give women more family planning options.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed around 119,000 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.